The relationship between female hormone use and primary liver cancer was analysed using data from a case-control study conducted between 1984 and 1992 in Milan on 82 female incident cases with histologically or serologically confirmed hepatocellular carcinoma and 368 controls admitted to hospital for acute non-neoplastic, non-hormone-related diseases. An elevated relative risk (RR) or primary liver cancer was observed in oral contraceptive (OC) users (RR 2.6, for ever versus never users, 95% confidence interval, CI 1.0-7.0). The RR was directly related to duration of use (RR 1.5 for A5 years and 3.9 for >5 years) and persisted for longer than 10 years after stopping use (RR 4.3%, 95% CI 1.0-18.2). The RR were below unity, although not significantly, for women ever using oestrogen replacement therapy (RR 0.2, 95% CI 0.03-1.5) and female hormones for indications other than contraception and menopausal therapy (RR 0.4, 95% CI 0.1 -1.5). The long-lasting, association between risk of hepatocellular carcinoma and OC use has potential implications on a public health scale, since primary liver cancer is a relatively rare disease among young women, but much more common at older ages. This study provides limited but reassuring evidence on the possible relationship between oestrogen replacement treatment and subsequent risk of hepatocellular carcinoma.
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There is evidence from several case-control studies of a positive association between the use of oral contraceptives (OC) and primary liver cancer in developed countries (Henderson et al., 1983; Neuberger et al., 1986; La Vecchia et al., 1989; Palmer et al., 1989; Yu et al., 1991; Hsing et al., 1992; Trichopoulos, 1992; WHO, 1992) , although data are inconsistent for developing countries (WHO, 1989) . This association is biologically plausible, as OCs are promoters of hepatocarcinogenesis in rodents (Yager & Yager, 1980) and the pill is known to increase the risk of adenoma of the liver in humans (Baum et al., 1973; Mettlin & Natarajan, 1981) .
In Italy, mortality from primary liver cancer in women below age 45 is extremely low, although some upward trend between the 1950s and the 1980s has been observed in young women, but not in young men (Decarli & La Vecchia, 1984) . This may support an involvement of OC use in the pathogenesis of this cancer. A case-control study found a significantly increased risk of hepatocellular carcinoma in Italian women 32-59, who had used the pill for longer than 5 years (La Vecchia et al., 1989 Relative risks (RR) of liver cancer and the corresponding 95% confidence intervals (CI) in relation to OC, oestrogen replacement treatment and female hormones for other indications were estimated, after adjustment for age, by the method described by Mantel and Haenszel (1959) ; for multiple levels of exposure, the significance of the linear trend in risk was assessed by the Mantel test (Breslow & Day, 1980) . Unconditional multiple logistic regression, fitted by the method of maximum likelihood, was used to allow for possible confounding factors (Breslow & Day, 1980) . The regression models included terms for age, education, parity and, in turn, ever use of OC, duration of use and time since last use. Further inclusion in the regression models of terms for alcohol and tobacco (which were not significantly related to hepatocellular carcinoma in Italian women) did not appreciably modify any of the estimates.
Results
Various measures of OC use in women below age 60 are considered in Table I . A total of nine (21%) cases and 21 (11%) controls had ever used the pill. The corresponding RR was 2.3 (95% CI 1.0-5.4). The risk increased with duration, with RRs of 1.5 for a use of < 5 years and 2.6 for longer use. The RR was 1.2 (95% CI 0.3-4.9) in women who had stopped OC use 10 years before or less, but was significantly elevated for those who had stopped more than 10 years earlier (RR 3.5, 95% CI 1.0-12.0). These risk estimates did not appreciably change after allowance for age, education and parity.
Relative risks for use of oestrogen replacement therapies and female hormones for other indications are reported in Table II . One case (1%) versus 19 (5%) controls had ever used oestrogens for post-menopausal symptoms; correspond-A. TAVANI et al. 0.4 (0.1-1.5) "Mantel-Haenszel estimates adjusted for age. bReference category.
ing numbers for other female hormones were two (2%) cases and 24 (7%) controls. None of the RRs were significant, though the risk estimates were below unity (0.2 for oestrogen replacement therapies and 0.4 for other female hormones).
Discussion
The results of this case-control study confirm an increased risk of primary liver cancer in OC users (Henderson et al., 1983; Neuberger et al., 1986; Forman et al., 1986; La Vecchia et al., 1989; Palmer et al., 1989; Yu et al., 1991; Hsing et al., 1992; Trichopoulos, 1992; WHO, 1992) , and, more importantly, indicate that the risk persists for 10 or more years after stopping treatment.
Primary liver cancer in Italy is relatively rare among young women, but much more common in older age groups (Decarli & La Vecchia, 1984) . Thus, the finding that the risk persists so long after stopping OC use has relevant implications on a public health scale, as the risk remains high at ages at which hepatocellular carcinoma becomes more frequent.
The observation of the time pattern of the risk of OC is not consistent with a promotional and, hence, rapidly emerging effect. Conversely the long-lasting influence of OC use on risk of hepatocellular carcinoma is similar to that described for pregnancy and birth (Trichopoulos, 1992; Stanford et al., 1992; Tzonou et al., 1992; Le Vecchia et al., 1992) , confirming that the effect of contraceptives on the risk of several neoplasms compares well to that of pregnancy (La Vecchia et al., 1990) .
Our findings that oestrogen replacement therapies and use of female hormones for other indications do not enhance the risk of liver cancer are in agreement with those of a Swedish cohort study (Adami et al., 1989) A potential limitation of this study is its hospital-based design (Mantel & Haenszel, 1959) , with all the consequent implications, such as the lack of information on total number of incident liver cancers and the exclusion of cases who died before interview. Moreover, only clinical of hepatitis was investigated and hepatitis B serum markers were not measured, thus precluding the possibility of adequately investigating possible interactions or viral carcinogenesis with hormone use.
In conclusion, the indication emerging from this study of a long-lasting increase in the risk of hepatocellular carcinoma in OC users is of interest to quantify the ultimate risks and benefits of OC use. The evidence is limited, but reassuring, for oestrogen replacement therapy.
